Abstract. The present study was undertaken in order to establish the significance of glucagon in glucose intolerance in liver cirrhosis. The plasma glucose response to an oral glucose load (75 g) was determined in 10 control subjects and in 10 cirrhotic patients, after infusions of: glucagon (3 ng\ m=. \ kg\ m=-\ 1\ m=. \ mi n\ m=-\ 1) or saline (154 mmol/l); somatostatin (SRIH) (500 \g=m\g/h);and SRIH plus glucagon (3 ng\ m=. \ kg\ m=-\ 1\ m=. \ mi n\ m=-\ 1). Glucagon infusion did not impair glucose tolerance, neither in normal subjects nor in patients with cirrhosis. On the other hand, in both groups glucose tolerance was impaired by SRIH infusion, presumably owing to an absolute insulin deficiency. Both in normal subjects and in cirrhotic patients, SRIH plus glucagon infusion further impaired glucose tolerance, presumably as a result of excess glucagon and concomitant insulin deficiency. In conclusion, our data show that hyperglucagonemia is not an important factor in the development of the glucose intolerance in patients with hepatic cirrhosis.
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Cirrhosis of the liver is characterized by an altered glucose tolerance (Megyesi et al. 1967; Samaan et al. 1969) , an increased concentration of insulin in the peripheral blood (Johnston et al. 1977; Iwasakietal. 1978; Greco et al. 1979) , an increase in plasma glucagon (Marco et al. 1973; Greco et al. 1974; Sherwin et al. 1974 ; Smith-Laing et al. 1980 ) and resistance to exogenous and endo¬ genous insulin, the latter being expressed as a reduction in insulin binding in the cell membrane (Greco et al. 1980a; Blei et al. 1982) . Although the mechanisms involved in the genesis of glucose intolerance are still unclear, glucagon has been considered to be one of the principal causes of this intolerance.
According to Felig et al. ( 1976) Catheters were introduced into the antecubital veins of both arms, one being used for drawing blood and the other for the infusion of SRIH, saline and glucagon. All infusions were delivered using Braun infusion pumps (Infusomat Secura, FRG Glucagon was measured radioimmunologically with Unger's 30 antiserum (Unger et al. 1962 (Fig. 4) Plasma glucose, glucagon and insulin before and after 75 g OGTT under infusion of glucagon (3 ng-kg"1-min"1).
Legends as in Fig. 1 owing to a decreased peripheral sensitivity to glucagon (Sherwin et al. 1978 ). All these hypotheses offer an explanation as to why peripheral and portal glucagon levels are increased, but do not explain the role played by glucagon in the genesis of glucose intolerance.
Our results show that in liver cirrhosis, glu¬ cagon infusion produces only a small increase in plasma glucose. Glucose intolerance was evident in all the cirrhotic patients in our experiments (saline, glucagon, SRIH, SRIH plus glucagon). Plasma glucose, glucagon and insulin before and after infusion of somatostatin (500 µg/h). Legends as in Fig. 1. No difference between the plasma glucose curve patterns of cirrhotic patients and normal subjects was seen when comparing glucagon and saline infusion. However, the addition of glucagon contributed to a further deterioration of glu¬ cose tolerance in both groups during infusion of SRIH. A significant reduction in glucagon level after OGTT has been observed by several authors (Smith-Laing et al. 1980; Marco et al. 1973 ). Our present and previous data (Greco et al. 1974 ), however, demonstrate a stability of the glucagon level during the administration of glucose in cirrhotic patients. This difference could be ex¬ plained by the notably higher basal level of plas¬ matic glucagon in our population. The admini¬ stration of glucose alone is not sufficient to de¬ activate the mechanism responsible for the in¬ creased glucagon level whatever it might be (hypersécrétion, decreased hepatic degradation, etc.).
In normal individuals, more than two-thirds of an oral glucose load escape splanchnic removal; quantitatively the peripheral tissues play the dominant role in glucose disposal (Katz et al. 1982) . It is therefore improbable that glucagon, Legends as in Fig. 1 Our present and past results (Greco et al. 1980b) demonstrate that in cirrhotic patients glucagon exerts a mild hyperglycémie action; this action is more pronounced during an OGTT in hypoinsulinemic conditions. Our data do not support the existence of glucagon resistance in hepatic cir-Glucagon (3ng-kg'· min1) SRIH Legends as in Fig. 1 
